Market cap
₹39 Cr
Revenue (TTM)
₹4 Cr
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -60.40 | 25.12 | 25.09 |
| EBIT | 85.78 | 19.89 | -196.62 | -267.59 | -227.69 |
| Net Profit | 83.18 | 23.57 | -131.35 | -240.73 | -281.42 |
| EPS | 83.18 | 23.57 | -131.37 | -201.12 | -261.37 |
| Book Value | -- | -- | -2.40 | -8.52 | -5.45 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| -193.47 | -250.35 | -389.43 | -47.28 | -41.49 |
| Net Margin
| -163.41 | -157.25 | -277.62 | -44.21 | -42.48 |
| Return on equity
| -14.09 | -10.26 | -29.00 | -11.47 | -13.63 |
| Return on Capital
| -8.80 | -7.05 | -- | -8.54 | -8.28 |
| Return on Assets
| -9.16 | -6.62 | -20.38 | -8.41 | -8.35 |
| Debt to Equity (x)
| -- | -- | 0.05 | 0.16 | 0.22 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
-8.54
|
-8.28
|
-9.58
|
-3.75
|
|
Peer Median
|
--
|
14.72
|
18.85
|
11.60
|
--
|
ROE
-29.00
Lower than Peers by 39.86
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-29.00
|
-11.47
|
-13.63
|
-17.16
|
-2.60
|
|
Peer Median
|
10.86
|
11.67
|
14.92
|
11.46
|
--
|
ROA
-20.38
Lower than Peers by 27.12
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-20.38
|
-8.41
|
-8.35
|
-10.73
|
-1.70
|
|
Peer Median
|
6.74
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
-389.43
Lower than Peers by 402.12
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-389.43
|
-47.28
|
-41.49
|
-491.62
|
-477.32
|
|
Peer Median
|
12.69
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
-277.62
Lower than Peers by 286.48
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-277.62
|
-44.21
|
-42.48
|
-403.54
|
-158.59
|
|
Peer Median
|
8.86
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
0.00
|
-38.82
|
-36.86
|
-502.58
|
-69.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-60.40
Lower than Peers by 68.54
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-60.40
|
-2.07
|
924.99
|
154.36
|
-68.84
|
|
Peer Median
|
8.14
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
-196.62
Lower than Peers by 213.87
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-196.62
|
-11.59
|
13.49
|
-161.98
|
23.35
|
|
Peer Median
|
17.24
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
-131.35
Lower than Peers by 148.20
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-131.35
|
-3.03
|
20.31
|
-537.18
|
55.76
|
|
Peer Median
|
16.85
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
-131.37
Lower than Peers by 141.97
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-131.37
|
21.05
|
36.55
|
-524.27
|
55.76
|
|
Peer Median
|
10.60
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
27.38
|
16.69
|
-13.83
|
7.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.05
Higher than Peers by 0.01
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
0.05
|
0.16
|
0.22
|
0.33
|
0.35
|
|
Peer Median
|
0.04
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
0.11
|
0.12
|
0.13
|
0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.92
Lower than Peers by 0.80
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
0.92
|
1.19
|
0.92
|
1.58
|
1.86
|
|
Peer Median
|
1.72
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
0.26
Lower than Peers by 0.91
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
0.26
|
0.53
|
0.45
|
1.03
|
1.13
|
|
Peer Median
|
1.17
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
-11.86
Lower than Peers by 19.73
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-11.86
|
-4.47
|
-3.17
|
-3.38
|
-1.91
|
|
Peer Median
|
7.86
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
8.17
Lower than Peers by 17.62
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
8.17
|
33.68
|
40.71
|
1,120.94
|
2,651.80
|
|
Peer Median
|
25.79
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
0.07
Lower than Peers by 0.60
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
0.07
|
0.18
|
0.19
|
0.02
|
0.01
|
|
Peer Median
|
0.67
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
137.33
|
273.88
|
3,948.36
|
5,842.77
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
271.84
|
256.57
|
3,091.84
|
8,791.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
284.27
|
312.19
|
849.73
|
5,212.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
124.89
|
218.25
|
6,190.47
|
9,421.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-3.32
Lower than Peers by 43.22
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-3.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.90
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
1.10
Lower than Peers by 3.13
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
1.10
|
1.46
|
1.41
|
1.03
|
0.96
|
|
Peer Median
|
4.23
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
-3.49
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
-3.49
|
-20.30
|
-18.08
|
-10.51
|
-42.12
|
|
Peer Median
|
--
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
39
Lower than Peers by 7,574
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Vista Pharma
|
39
|
66
|
50
|
31
|
34
|
|
Peer Median
|
7,613
|
4,851
|
2,099
|
15,272
|
--
|